Rocket Pharmaceuticals (RCKT) Other Non-Current Assets (2014 - 2026)

Rocket Pharmaceuticals has disclosed Other Non-Current Assets across 13 years of filings, most recently posting $482000.0 for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $482000.0, down 6.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $482000.0 (down 6.23% YoY), and the FY2025 annual result was $482000.0, down 8.88% from the prior year.
• Other Non-Current Assets came in at $482000.0 for Q1 2026 at Rocket Pharmaceuticals, roughly flat from $482000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $608000.0 in Q4 2022 to a low of $455000.0 in Q1 2022.
• The 5-year median for Other Non-Current Assets is $514000.0 (2025), against an average of $506058.8.
• Across the five-year window, Other Non-Current Assets soared 33.63% in 2022 and retreated 12.34% in 2023, its largest moves.
• Rocket Pharmaceuticals' Other Non-Current Assets stood at $608000.0 in 2022, then decreased by 12.34% to $533000.0 in 2023, then slipped by 0.75% to $529000.0 in 2024, then dropped by 8.88% to $482000.0 in 2025, then changed by 0.0% to $482000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $482000.0 (Q1 2026), $482000.0 (Q4 2025), and $515000.0 (Q3 2025), per Business Quant data.